AR056838A1 - Derivados de 1,2,5-tiadiazol - Google Patents
Derivados de 1,2,5-tiadiazolInfo
- Publication number
- AR056838A1 AR056838A1 ARP060105392A ARP060105392A AR056838A1 AR 056838 A1 AR056838 A1 AR 056838A1 AR P060105392 A ARP060105392 A AR P060105392A AR P060105392 A ARP060105392 A AR P060105392A AR 056838 A1 AR056838 A1 AR 056838A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- alkoxy
- heterocyclyl
- cycloalkyl
- aryl
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 alkyloxy-alkoxy Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000003627 8 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REIVINDICACIoN 1.- Un compuesto de la Formula (I) en donde: Q, combinado junto con los átomos de carbono con los que está unido, forma un anillo carbocíclico o heterocíclico de 5 a 8 miembros, aromático, o no aromático parcial o completamente saturado; R1es hidrogeno, -C(O)R6, -C(O)NR7R8, o -C(O)OR9, en donde: R6 y R7 son, independientemente uno del otro, hidrogeno, cicloalquilo, arilo, heterociclilo, aralquilo, heteroaralquilo, o alquilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, cicloalquilo, cicloalcoxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquilamino, dialquil-amino, arilo, ariloxilo, y heterociclilo; R8 y R9 son, independientemente uno del otro, cicloalquilo, arilo, heterociclilo, aralquilo, heteroaralquilo, o alquilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, cicloalquilo, cicloalcoxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquil-amino, dialquil-amino, arilo, ariloxilo, y heterociclilo; R2, R3, R4 y R5 son, independientemente unos de otros, hidrogeno, hidroxilo, halogeno, ciano, nitro, alcoxilo, tioalquilo, tionoalquilo, sulfonilo, carboxilo libre o esterificado, carbamoílo, sulfamoílo, amino opcionalmente sustituido, cicloalquilo, arilo, heterociclilo, alquenilo, alquinilo, o alquilo (de 1 a 8 átomos de carbono) opcionalmente sustituido por 1 a 4 sustituyentes seleccionados a partir del grupo que consiste en halogeno, hidroxilo, cicloalquilo, cicloalcoxilo, acilo, aciloxilo, alcoxilo, alquiloxi-alcoxilo, amino, alquil-amino, dialquil-amino, acil-amino, carbamoílo, tiol, rioalquilo, tionoalquilo, sulfonilo, sulfonamido, sulfamoílo, nitro, ciano, carboxilo libre o esterificado, arilo, ariloxílo, tioarílo, alquenilo, alquinilo, aralcoxilo, heteroaralcoxilo, heterociclilo, y heterocicliloxilo; o R2 y R3 combinados son alquileno que, junto con los átomos del anillo con los que están unidos, forman un anillo fusionado de 3 a 7 miembros; o R2 y R3 combinados son alquileno que, junto con el átomo de carbono con el que están unidos, forman un anillo espirocíclico de 3 a 7 miembros; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74857305P | 2005-12-08 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056838A1 true AR056838A1 (es) | 2007-10-24 |
Family
ID=37950917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105392A AR056838A1 (es) | 2005-12-08 | 2006-12-06 | Derivados de 1,2,5-tiadiazol |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7700633B2 (es) |
| EP (1) | EP1963292B1 (es) |
| JP (1) | JP2009519248A (es) |
| KR (1) | KR20080074969A (es) |
| CN (1) | CN101326173A (es) |
| AR (1) | AR056838A1 (es) |
| AT (1) | ATE546440T1 (es) |
| AU (1) | AU2006321905B2 (es) |
| BR (1) | BRPI0619600A2 (es) |
| CA (1) | CA2629857A1 (es) |
| CR (1) | CR10049A (es) |
| EC (1) | ECSP088506A (es) |
| ES (1) | ES2381280T3 (es) |
| IL (1) | IL191549A0 (es) |
| MA (1) | MA30202B1 (es) |
| NO (1) | NO20083031L (es) |
| NZ (1) | NZ568243A (es) |
| PE (2) | PE20100733A1 (es) |
| PL (1) | PL1963292T3 (es) |
| PT (1) | PT1963292E (es) |
| RU (1) | RU2008127254A (es) |
| TN (1) | TNSN08249A1 (es) |
| TW (1) | TW200732315A (es) |
| UA (1) | UA94724C2 (es) |
| WO (1) | WO2007067615A2 (es) |
| ZA (1) | ZA200804074B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080074970A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ｐｔｐａｓｅ)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
| CN101321743A (zh) * | 2005-12-08 | 2008-12-10 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途 |
| UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| WO2008067527A1 (en) * | 2006-12-01 | 2008-06-05 | Novartis Ag | Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders |
| AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| JP7579057B2 (ja) | 2016-12-23 | 2024-11-07 | ザ ユニバーシティー オブ クイーンズランド | 血管新生および／またはリンパ脈管新生関連の疾病の処置のためのｓｏｘ１８タンパク質活性の阻害剤 |
| TWI888352B (zh) * | 2018-06-21 | 2025-07-01 | 美商嘉來克生命科學有限責任公司 | 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法 |
| EP3898618A1 (en) | 2018-12-21 | 2021-10-27 | Crystal Pharma, S.A.U. | Process and intermediates for the preparation of voxelotor |
| TW202519515A (zh) * | 2019-03-14 | 2025-05-16 | 美商嘉來克生命科學有限責任公司 | 蛋白酪胺酸磷酸酶抑制劑及其使用方法 |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| CN116194453A (zh) * | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| CN117279913A (zh) * | 2021-03-11 | 2023-12-22 | 金橘生物科技公司 | 杂环化合物及其用途 |
| CN118525016A (zh) * | 2021-11-11 | 2024-08-20 | 卡里科生命科学有限责任公司 | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 |
| EP4472957A1 (en) * | 2022-02-02 | 2024-12-11 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
| WO2023150523A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
| WO2023150535A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
| CN119790052A (zh) * | 2022-09-13 | 2025-04-08 | 金橘生物科技公司 | 苯并稠合的n-杂环及其用途 |
| WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
| WO2024141015A1 (en) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Protein tyrosine phosphatase inhibitors and uses thereof |
| CN118852335A (zh) * | 2023-04-28 | 2024-10-29 | 中科中山药物创新研究院 | 噻二唑烷酮衍生物及其制备方法和应用 |
| CN116496248B (zh) * | 2023-05-06 | 2025-09-02 | 江苏艾科姆检测有限公司 | 一种溴氰虫酰胺杂质的合成方法 |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025011570A1 (zh) * | 2023-07-11 | 2025-01-16 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途 |
| CN120004876A (zh) * | 2023-11-16 | 2025-05-16 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| WO2025242216A1 (zh) * | 2024-05-24 | 2025-11-27 | 杭州百新生物医药科技有限公司 | 吲哚啉类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2341049A1 (en) * | 2002-04-03 | 2011-07-06 | Novartis AG | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors |
| GB0225986D0 (en) | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
| US7432292B2 (en) * | 2002-12-30 | 2008-10-07 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres |
| US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| KR20080074970A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ｐｔｐａｓｅ)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
| CN101321743A (zh) * | 2005-12-08 | 2008-12-10 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途 |
| AU2007233251A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Thiadiazolidinone inhibitors of PTPase |
-
2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 CA CA002629857A patent/CA2629857A1/en not_active Abandoned
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 EP EP06839094A patent/EP1963292B1/en active Active
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Ceased
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/en not_active Ceased
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
-
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2381280T3 (es) | 2012-05-24 |
| AU2006321905B2 (en) | 2011-08-11 |
| CA2629857A1 (en) | 2007-06-14 |
| US20080262050A1 (en) | 2008-10-23 |
| PL1963292T3 (pl) | 2012-07-31 |
| NO20083031L (no) | 2008-08-28 |
| KR20080074969A (ko) | 2008-08-13 |
| BRPI0619600A2 (pt) | 2011-10-11 |
| WO2007067615A2 (en) | 2007-06-14 |
| PE20100733A1 (es) | 2010-10-29 |
| CN101326173A (zh) | 2008-12-17 |
| EP1963292A2 (en) | 2008-09-03 |
| US7700633B2 (en) | 2010-04-20 |
| CR10049A (es) | 2008-08-25 |
| JP2009519248A (ja) | 2009-05-14 |
| IL191549A0 (en) | 2008-12-29 |
| WO2007067615A3 (en) | 2007-11-15 |
| PE20071031A1 (es) | 2007-11-15 |
| PT1963292E (pt) | 2012-05-10 |
| ECSP088506A (es) | 2008-07-30 |
| AU2006321905A1 (en) | 2007-06-14 |
| TW200732315A (en) | 2007-09-01 |
| ATE546440T1 (de) | 2012-03-15 |
| ZA200804074B (en) | 2009-03-25 |
| UA94724C2 (en) | 2011-06-10 |
| MA30202B1 (fr) | 2009-02-02 |
| RU2008127254A (ru) | 2010-01-20 |
| NZ568243A (en) | 2011-07-29 |
| TNSN08249A1 (en) | 2009-10-30 |
| EP1963292B1 (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
| AR056548A1 (es) | Derivados de sulfonamidas, composiciones farmaceuticas y sus usos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR056109A1 (es) | Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR048820A1 (es) | Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3) | |
| AR035517A1 (es) | Derivados de piperazina, proceso para prepararlos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la elaboracion de medicamentos | |
| AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR035518A1 (es) | Derivados de carboxamida, un procedimiento para su preparacion, un medicamento que los contiene, el u so de los mismos para preparar un medicamento, y un conjunto (kit) que los incluye | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR048241A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR062110A1 (es) | Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| ECSP034660A (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |